Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • CDK
    (3)
  • PLK
    (1)
  • PROTACs
    (1)
  • Others
    (1)
Filter
Search Result
Results for "

cdk8 in 1

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    8
    TargetMol | Inhibitors_Agonists
  • PROTAC Products
    1
    TargetMol | PROTAC
CDK8-IN-1
T107401629633-48-2In house
CDK8-IN-1 is a selective CDK8 inhibitor (IC50: 3 nM).
  • Inquiry Price
6-8 weeks
Size
QTY
CDK8/19-IN-1
T107391818427-07-4
CDK8 19-IN-1 is a selective, orally bioavailable dual inhibitor of CDK8 and CDK19, with IC50 values of 0.46 nM for CDK8, 0.99 nM for CDK19, and 270 nM for [CDK9].
  • Inquiry Price
6-8 weeks
Size
QTY
3mb-pp1
T21678956025-83-5In house
3MB-PP1 is a bulky purine analog and a Polo-like kinase 1 (Plk1) inhibitor. In cells expressing analog-sensitive Plk1 alleles, 3MB-PP1 blocks mitotic progression and cell division arise by targeting Plk1. 3MB-PP1 specifically inhibits analog-sensitive Ssn3 (Cdk8). 3MB-PP1 inhibits Leu93 Mutant Zipper-interacting protein kinase with IC50 of 2 μM. 3MB-PP1 can be used for the research of cell division and hypha formation of Candida albicans.
  • Inquiry Price
Size
QTY
BI-1347
T54052163056-91-3
BI-1347 is a potent, selective inhibitor of CDK8 cyclinC (IC50: 1 nM). It shows tumor growth inhibition in an in vivo xenograft model.
  • Inquiry Price
Size
QTY
MK256
MK-256, MK 256
T2024072271348-04-8
MK256 is a novel CDK8 inhibitor that demonstrates potent antitumor activity against AML by inhibiting the STAT pathway. It induces differentiation and maturation while inhibiting proliferation in AML cell lines. MK256 decreases the phosphorylation of STAT1(S727) and STAT5(S726) and reduces mRNA expression of MCL-1 and CCL2 in these cells. Its efficacy is validated in the MOLM-14 xenograft model, showing phosphorylation inhibition of STAT1(S727) and STAT5(S726) post-treatment. Pharmacokinetic studies in the MOLM-14 model reveal a dose-dependent inhibition of the STAT pathway. Both in vitro and in vivo studies confirm that MK256 effectively downregulates the STAT pathway.
  • Inquiry Price
Size
QTY
ll-k8-22
T74784
LL-K8-22 is a potent, selective, and durable dual degrader of CDK8-cyclin C, demonstrating DC50 values of 2.52 and 2.64 μM, respectively. This compound effectively suppresses STAT1 Ser 727 phosphorylation and inhibits carcinogenic transcriptional programs driven by E2F and MYC. LL-K8-22 is specifically utilized in research for triple-negative breast cancer (TNBC) [1].
  • Inquiry Price
Size
QTY
SNX7886
T811372924557-42-4
SNX7886 is a potent PROTAC (proteolysis-targeting chimera) that effectively degrades CDK8 and CDK19, achieving 90% degradation of CDK8 and 80% degradation of CDK19 in 293 cells [1].
  • Inquiry Price
Size
QTY
CDK8-IN-14
T860312924193-12-2
CDK8-IN-14 (compound 12) effectively inhibits CDK8, demonstrating an IC50 of 39.2 nM, and exhibits potent anti-AML cell proliferation effects, with a GC50 value of 0.02±0.01μM in MOLM-13 cells and 0.03±0.01μM in MV4-11 cells [1].
  • Inquiry Price
10-14 weeks
Size
QTY